Maja J.A. de Jonge

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020 · 997 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Johanna C. Bendell, Jordi Rodón, Howard A. Burris et al. · Journal of Clinical Oncology · 2011 · 686 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

Jordi Rodón, Guillem Argilés, Roisín M. Connolly et al. · British Journal of Cancer · 2021 · 160 citations · Full text

Medicine, Oncology, Pharmacology +6

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong et al. · Gynecologic Oncology · 2018 · 130 citations

Medicine, Oncology, Pharmacology +16

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

Maja J.A. de Jonge, Vincent A. de Weger, Mark A. Dickson et al. · European Journal of Cancer · 2017 · 126 citations

Medicine, Oncology, Pharmacology +8